The Medical Letter on Drugs and Therapeutics
FROM
ISSUE
962
November 24, 1995
View Complete Issue         Table of Contents 2019 
Dexrazoxane for Cardiac Protection Against Doxorubicin
Subscribers: Log in to read full article.  Not a subscriber?  Subscribe or purchase article.
Dexrazoxane for Cardiac Protection Against Doxorubicin
November 24, 1995 (Issue: 962)
Dexrazoxane (Zinecard - Pharmacia) was recently approved by the US Food and Drug Administration (FDA) for protection against cardiac toxicity from (Adriamycin, and others) in women with metastatic breast cancer.
The Medical Letter is a subscriber-funded nonprofit organization that publishes critical appraisals of new prescription drugs and comparative reviews of drugs for common diseases.

Would you like to read the rest of this article?  Gain access below.

Subscribe
Subscriptions to The Medical Letter on Drugs and Therapeutics include:
  • Print version published and mailed biweekly (26 issues/year)
  • Unlimited online access to current and past issues (1988 - present)
  • Mobile App
  • FREE online per issue CME/CE
Purchase this article:
Title: Dexrazoxane for Cardiac Protection Against Doxorubicin
Article code: 962b
 Electronic, downloadable article - $45


Gain access through your organization
Ask your librarian to consider an Institutional Subscription to The Medical Letter.